Skip to main content
SpringerLink
Log in

Vascular-Targeted Photodynamic Therapy for Prostate Cancer

  • Chapter
  • First Online:
Interventional Urology

Abstract

Vascular-targeted photodynamic therapy (VTP) is an approved focal treatment for prostate cancer which is minimally invasive and performed in the ambulatory setting. VTP is administered using a photosensitizer that is delivered intravenously and activated locally by laser fibers that emit a specific wavelength of light. Once activated, the photosensitizer generates free radicals, causing a severe form of uniform local vascular injury within tissues, resulting in a controlled, non-thermal form of coagulative tissue necrosis that is tumoricidal and associated with minimal side effects or collateral tissue damage.

The development of prostate cancer VTP has rapidly advanced over the past few decades, with a maturing body of evidence supporting its clinical utility and adoptability to a number of relevant applications (Scherz et al., Vascular-targeted photodynamic therapy in prostate cancer: From bench to clinic. In: Kostron H, Hasan T, editors. Photodynamic medicine: from bench to clinic. Cambridge: Royal Society of Chemistry:461–480, 2016). In 2017, the European Medicines Agency approved VTP with WST-11 (Padeliporfin, TOOKAD Soluble; Steba Biotech S.A.) for the treatment of men with low-risk prostate cancer based on results from a phase III randomized controlled trial (Azzouzi et al., Lancet Oncol. 18(2):181–91, 2017; Gill et al., J Urol. 200(4):786–793, 2018). Additional trials are underway investigating treatment for men with intermediate-risk prostate cancer, including phase II trials in the USA (NCT03315754). The strong supporting evidence from clinical trials and preclinical studies with VTP demonstrates the significant potential of this therapy as a mainstay treatment for prostate cancer focal therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Scherz A, Salomon Y, Lindner U, Coleman J. Vascular-targeted photodynamic therapy in prostate cancer: From bench to clinic. In: Kostron H, Hasan T, editors. Photodynamic medicine: from bench to clinic. Cambridge: Royal Society of Chemistry; 2016. p. 461–80.

    Chapter  Google Scholar 

  2. Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(2):181–91.

    Article  CAS  Google Scholar 

  3. Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. J Urol. 2018;200(4):786–93.

    Article  Google Scholar 

  4. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol. 2018;199(4):990–7.

    Article  Google Scholar 

  5. Kimm SY, Tarin TV, Monette S, Srimathveeravalli G, Gerber D, Durack JC, et al. Nonthermal ablation by using intravascular oxygen radical generation with WST11: dynamic tissue effects and implications for focal therapy. Radiology. 2016;281(1):109–18.

    Article  Google Scholar 

  6. Murray KS, Winter AG, Corradi RB, LaRosa S, Jebiwott S, Somma A, et al. Treatment effects of WST11 vascular targeted photodynamic therapy for urothelial cell carcinoma in swine. J Urol. 2016;196(1):236–43.

    Article  Google Scholar 

  7. Mazor O, Brandis A, Plaks V, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol. 2005;81(2):342–51.

    Article  CAS  Google Scholar 

  8. Madar-Balakirski N, Tempel-Brami C, Kalchenko V, Brenner O, Varon D, Scherz A, Salomon Y. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One. 2010;5(4):e10282.

    Article  Google Scholar 

  9. Brandis A, Mazor O, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A. Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol. 2005;81(4):983–93.

    Article  CAS  Google Scholar 

  10. Ashur I, Goldschmidt R, Pinkas I, Salomon Y, Szewczyk G, Sarna T, Scherz A. Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin. J Phys Chem A. 2009;113(28):8027–37.

    Article  CAS  Google Scholar 

  11. Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci. 2011;10(5):681–8.

    Article  CAS  Google Scholar 

  12. Lebdai S, Gigoux M, Alvim R, Somma A, Nagar K, Azzouzi AR, et al. Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. Onco Targets Ther. 2019;8(6):e1581528.

    Google Scholar 

  13. Corradi RB, LaRosa S, Jebiwott S, Murray KS, Rosenzweig B, Somma AJ, et al. Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma. Int J Urol. 2019;26(3):414–22.

    Article  CAS  Google Scholar 

  14. Kim K, Watson PA, Lebdai S, Jebiwott S, Somma AJ, La Rosa S, et al. Androgen deprivation therapy potentiates the efficacy of vascular targeted photodynamic therapy of prostate cancer xenografts. Clin Cancer Res. 2018;24(10):2408–16.

    Article  CAS  Google Scholar 

  15. O'Shaughnessy MJ, Murray KS, La Rosa SP, Budhu S, Merghoub T, Somma A, et al. Systemic antitumor immunity by PD-1/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors. Clin Cancer Res. 2018;24(3):592–9.

    Article  CAS  Google Scholar 

  16. Azzouzi AR, Barret E, Moore CM, Villers A, Allen C, Scherz A, et al. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int. 2013;112(6):766–74.

    Article  CAS  Google Scholar 

  17. Moore CM, Azzouzi AR, Barret E, Villers A, Muir GH, Barber NJ, et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU Int. 2015;116(6):888–96.

    Article  CAS  Google Scholar 

  18. Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, et al. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol. 2015;33(7):945–53.

    Article  CAS  Google Scholar 

  19. Rodriguez-Rivera JA, Rodriguez-Lay R, Zegarra-Montes L, Benzaghou F, Gaillac B, Azzouzi AR, et al. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. Actas Urol Esp. 2018;42(10):632–8.

    Article  CAS  Google Scholar 

  20. Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, et al. Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD Soluble WST-11 (phase II trials). Eur Urol Focus. 2019;5(6):1022–8.

    Article  CAS  Google Scholar 

  21. Pierrard V, Lebdai S, Kleinclauss F, Azzouzi AR, Terrier JE, Fortier E, et al. Radical prostatectomy after vascular targeted photodynamic therapy with padeliporfin: feasibility, and early and intermediate results. J Urol. 2019 Feb;201(2):315–21.

    Article  Google Scholar 

  22. Lebdai S, Villers A, Barret E, Nedelcu C, Bigot P, Azzouzi AR. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® soluble focal treatment for localized prostate cancer. World J Urol. 2015;33(7):965–71.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Nathan C. Wong & Jonathan A. Coleman

  2. Department of Plants and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel

    Avigdor Scherz

  3. Division of Urology, Department of Surgery, University of Missouri, Columbia, MO, USA

    Katie S. Murray

Authors
  1. Nathan C. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Avigdor Scherz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan A. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katie S. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan A. Coleman .

Editor information

Editors and Affiliations

  1. Urology and Radiology, Lenox Hill Hospital, New York, NY, USA

    Ardeshir R. Rastinehad

  2. Vascular & Interventional Radiology, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA

    David N. Siegel

  3. National Cancer Institute & Clinica, Bethesda, MD, USA

    Bradford J. Wood

  4. Lefrak Center for Robotic Surgery, Weill Cornell Medicine, New York, NY, USA

    Timothy McClure

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wong, N.C., Scherz, A., Coleman, J.A., Murray, K.S. (2021). Vascular-Targeted Photodynamic Therapy for Prostate Cancer. In: Rastinehad, A.R., Siegel, D.N., Wood, B.J., McClure, T. (eds) Interventional Urology . Springer, Cham. https://doi.org/10.1007/978-3-030-73565-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-73565-4_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-73564-7

  • Online ISBN: 978-3-030-73565-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation